BBT001在健康志愿者(HVS)和成人特应性皮炎(AD)中的研究
一项随机,盲目的,安慰剂对照,单次和多重剂量研究,以评估BBT001和AD患者的安全性,耐受性,药代动力学,免疫原性,药效学和临床活性
This is a Phase 1, randomized, blinded, placebo controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).
研究概览
详细说明
This study a is a randomized, double-blinded, placebo-controlled single (SAD) and multiple-ascending dose (MAD) study to evaluate safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics, and exploratory clinical activity of BBT001 in healthy volunteers (HVs) and in adult patients with atopic dermatitis. BBT001 is a drug candidate being developed for the treatment of atopic dermatitis.
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Lisa Li
- 电话号码:+1 617-848-6188
- 邮箱:Lisa.Li@bambusatx.com
学习地点
-
-
-
Christchurch、新西兰
- 招聘中
- Optimal Clinical Trials Ltd - Christchurch
-
Upper Hutt、新西兰、5018
- 招聘中
- Pacific Clinical Research Network (PCRN) Wellington
-
接触:
- Tim Humphrey
-
-
Auckland
-
Grafton、Auckland、新西兰、1010
- 招聘中
- Optimal Clinical Trials Central Auckland
-
接触:
- Arna Letica
-
Otahuhu、Auckland、新西兰、2025
- 撤销
- Aotearoa Clinical Trials
-
Takapuna、Auckland、新西兰、0622
- 招聘中
- Pacific Clinical Research Network (PCRN) - Auckland
-
接触:
- Paul Hamilton
-
-
-
-
-
Lodz、波兰、91-347
- 招聘中
- Wojewódzki Specjalistyczny Szpital im. Dr. Wł. Biegańskiego w Łodzi
-
Rzeszów、波兰、35-055
- 招聘中
- Uniwersytecki Szpital Kliniczny im. Fryderyka Chopina w Rzeszowie
-
Warsaw、波兰、02-507
- 招聘中
- Państwowy Instytut Medyczny MSWiA
-
Wroclaw、波兰、50-566
- 招聘中
- Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak Spółka Partnerska
-
-
-
-
Western Australia
-
Fremantle、Western Australia、澳大利亚、6160
- 招聘中
- Fremantle Dermatology
-
Perth、Western Australia、澳大利亚、6009
- 完全的
- Linear Clinical Research
-
-
-
-
California
-
Irvine、California、美国、92614
- 招聘中
- First OC Dermatology
-
-
New York
-
New York、New York、美国、10128
- 招聘中
- OptiSkin Medical
-
The Bronx、New York、美国、10455
- 招聘中
- Equity Medical, LLC
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Key Inclusion Criteria
- Negative pregnancy tests for women of childbearing potential.
- Willingness to refrain from alcohol consumption for 24 hours prior to each study visit.
- Non-smokers, healthy current smokers (≤5 cigarettes/day), or ex-smokers.
- Adequate contraception use (for men and women of childbearing potential).
Key Inclusion Criteria (Parts A, B, and D)
- Age of 18-65 years.
- Body mass index of 18 to 32 kg/m², weight capped at 120 kg.
- No clinically significant abnormalities or history of relevant diseases.
Key Inclusion Criteria (Parts C and E only)
- Age of 18-72 years.
- Body mass index ≥16 kg/m², weight capped at 125 kg.
- Must have dermatologist-confirmed chronic atopic dermatitis (≥12 months). Inadequate response to topical treatments or where they are medically inadvisable.
- Moderate to severe atopic dermatitis
- Validated investigator's global assessment for atopic dermatitis (vIGA-ADTM) score ≥3
- Atopic lesions cover ≥10% of body surface area (BSA)
- Average peak pruritus numeric rating scale (PP-NRS) score ≥4 in the 7 days before randomization.
Key Exclusion Criteria
- Significant health issues, such as: diabetes, positive tests for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B surface antigen (HBsAg), immunodeficiencies, autoimmune diseases, or cancer, history of conditions predisposing to infections.
- History of major metabolic, dermatological, liver, kidney, hematological, or other significant disorders.
- Clinically relevant abnormal lab results, including low blood counts, liver issues, or abnormal kidney function.
- Positive drug/alcohol tests or abnormal vital signs at screening or Day -1.
- Abnormal Electrocardiogram (ECG) findings
- History of drug/alcohol abuse in the past 2 years.
- Donated >500mL blood within 2 months of screening.
- History of severe allergic reactions or hypersensitivity.
Key Exclusion Criteria (Parts A, B, and D only)
1. History of atopic dermatitis
Key Exclusion Criteria (Parts C and E only)
- Skin diseases other than atopic dermatitis, significant tattoos, or scarring.
- Receipt of immunoglobulin or blood products within 30 days.
- Atopic dermatitis with ocular symptoms or chronic ocular steroid use.
- Chronic pruritus from conditions other than atopic dermatitis.
- Acute/treated infections or chronic skin infections.
- Current use of sedating antihistamines or corticosteroids.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Part A Single Ascending Dose BBT001
A single dose of BBT001 will be administered in healthy volunteers |
BBT001 will be administered |
|
实验性的:Part B Multiple Ascending Dose BBT001
Multiple doses of BBT001 will be administered in healthy volunteers. |
BBT001 will be administered |
|
实验性的:Part C Multiple Ascending Dose BBT001
Multiple doses of BBT001 will be administered in patients with atopic dermatitis. |
BBT001 will be administered |
|
安慰剂比较:Part A Single Ascending Dose Placebo
A single dose of Placebo will be administered in healthy volunteers |
Placebo will be administered |
|
安慰剂比较:Part B Multiple Ascending Dose Placebo
Multiple doses of Placebo will be administered in healthy volunteers. |
Placebo will be administered |
|
安慰剂比较:Part C Multiple Ascending Dose Placebo
Multiple doses of Placebo will be administered in patients with atopic dermatitis. |
Placebo will be administered |
|
有源比较器:Part D Single Ascending Dose BBT001
A single dose of BBT001 will be administered in healthy volunteers |
BBT001 will be administered |
|
安慰剂比较:Part D Single Ascending Dose Placebo
A single dose of placebo will be administered in healthy volunteers |
Placebo will be administered |
|
有源比较器:Part E Multiple Ascending Dose BBT001 - Dose Level 1
Multiple doses of BBT001 will be administered in patients with atopic dermatitis. |
BBT001 will be administered |
|
安慰剂比较:Part E Multiple Ascending Dose Placebo
Multiple doses of placebo will be administered in patients with atopic dermatitis. |
Placebo will be administered |
|
有源比较器:Part E Multiple Ascending Dose BBT001 - Dose Level 2
Multiple doses of BBT001 will be administered in patients with atopic dermatitis |
BBT001 will be administered |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of participants with adverse events following single and multiple administration of BBT001
大体时间:Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
Incidence, relatedness, and severity of adverse events graded per NCI CTCAE v5.0. |
Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
|
Number of participants with change in serum blood parameters
大体时间:Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
Laboratory assessments include hematology, blood chemistry and coagulation test |
Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
|
Number of participants with change in vital sign measurements following treatment administration.
大体时间:Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
Blood pressure and heart rate will be assessed. |
Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
|
Number of participants with change in physical examination following treatment administration.
大体时间:Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
Physical examination will be assessed. |
Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
|
Number of participants with change in 12-lead ECG readings
大体时间:Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
12-lead ECG will be assessed. |
Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Pharmacokinetics parameters - maximum observed Concentration (Cmax)
大体时间:At specified timepoints pre-dose and up to 169 days post first dose administration
|
Maximum observed concentration of the study drug in serum will be analyzed for all subjects |
At specified timepoints pre-dose and up to 169 days post first dose administration
|
|
Pharmacokinetics parameters - Time for maximum observed Concentration (Tmax)
大体时间:At specified timepoints pre-dose and up to 169 days post first dose administration
|
Serum PK Tmax will be analyzed for all subjects |
At specified timepoints pre-dose and up to 169 days post first dose administration
|
|
Pharmacokinetics parameters - Area under the curve (AUC)
大体时间:At specified timepoints pre-dose and up to 169 days post first dose administration
|
Area under the curve of the study drug in serum will be analyzed for all subjects |
At specified timepoints pre-dose and up to 169 days post first dose administration
|
|
Pharmacokinetics parameters - Volume of distribution (Vz)
大体时间:At specified timepoints pre-dose and up to 169 days post first dose administration
|
Volume of distribution of the study drug in serum will be analyzed for all subjects |
At specified timepoints pre-dose and up to 169 days post first dose administration
|
|
Pharmacokinetics parameters - Total clearance (CL)
大体时间:At specified timepoints pre-dose and up to 169 days post first dose administration
|
Total clearance of the study drug in serum will be analyzed for all subjects |
At specified timepoints pre-dose and up to 169 days post first dose administration
|
|
Pharmacokinetics parameters - Elimination Half-life (t1/2).
大体时间:At specified timepoints pre-dose and up to 169 days post first dose administration
|
Elimination half-life of the study drug in serum will be analyzed for all subjects |
At specified timepoints pre-dose and up to 169 days post first dose administration
|
|
The immunogenicity of BBT001 is measured as the number and percentage of subjects who develop Anti-Drug Antibodies (ADA).
大体时间:At specified timepoints pre-dose and up to 169 days post first dose administration
|
Serum Anti-Drug Antibodies will be analyzed for all subjects |
At specified timepoints pre-dose and up to 169 days post first dose administration
|
合作者和调查者
调查人员
- 研究主任:Lisa Li、Bambusa Therapeutics, Inc.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.